Law Offices of Thomas J. Lamb

  • About Our Firm
  • Drug Injury
  • Asbestos & Mesothelioma
  • Benzene Diseases
  • Breast Implants
  • Free Case Evaluation
  • FAQs

Xeljanz Safety Concerns and New Precautions

August 6, 2019 By Law Offices of Thomas J. Lamb, P.A.

You may have read our previous articles about Xeljanz and its risk of leading to Pulmonary Embolism or even death.  In June, we posted “Xeljanz Related Blood Clots Can Cause Pulmonary Embolism (PE) Or Deep Vein Thrombosis (DVT) With Patient Deaths Possible“ that provides information on the serious side effects found out through a post-marketing study on the drug.  The FDA has finally put in place the “Black Box Warning” to draw attention to these serious risks.

Treatment and Trials

Xeljanz can be used to treat ulcerative colitis as well as psoriatic or rheumatoid arthritis.  The recent article, “FDA Requires Box Warnings for Pfizer Drug Xeljanz”, relays information from the FDA that the 10 mg dosage twice a day should not be used for the aforementioned types of arthritis, just ulcerative colitis.  Even further, it should only be used for ulcerative colitis if other medications are not sufficient for the patient.

The use of Xeljanz for the treatment of rheumatoid arthritis was discussed in the Milwaukee Journal Sentinel article, “FDA puts stringent warning on the Pfizer drug Xeljanz because of clots and deaths”, noting that:

The FDA also released data from a safety trial of the drug in people with rheumatoid arthritis, showing there were 19 blood clots in the lungs in those who got higher-dose Xeljanz compared with three who got other drugs known as TNF blockers. There also were 45 deaths in those who got high-dose Xeljanz compared with 25 who got TNF blockers.

The “Black Box Warning” came five months after this clinical trial.  The FDA has received public criticism, such as from physician Michael Carome with Public Citizen, for “moving more slowly and less aggressively to protect public health relative to regulators in other countries”

__________________________________________________________________

Xel­janz

Free Case Evaluation

Strictly Confidential, No Obligation.

__________________________________________________________________

 

New Safety Precautions

Medscape also just published an article on the subject, “FDA Adds Boxed Warning on Risk for PE, Death With Higher Dose Tofacitinib (Xeljanz)”, which reports that in May, health officials in Europe had already advised physicians against the twice a day 10 mg dose of the medicine due to high risk of PE.

Edward V. Loftus, Jr., MD, the Chief Medical Editor of Healio Gastroenterology and Liver Disease, notes:

Based on what I have read, I do not know what the actual magnitude of that risk is, in other words, what’s the relative risk or absolute risk for thromboembolism?

But, there must have been some signal at the higher dose that they saw this signal and so, the European’s put out the warning and now the FDA is basically putting out the same warning and they are making it a boxed warning.

While this is confusing, we just have to be cognizant of the warning, which is use the lowest dose possible that keeps your patient in remission.

As more information and developments arise regarding the safety of Xeljanz, we will make sure to provide updates whenever possible.

You can visit our law firm’s website to submit a free case evaluation if you think you or someone you know may have a personal injury or wrongful death lawsuit as a result of Xeljanz side effects.


Written by: Laura Beasley, Legal Assistant

Law Offices of Thomas J. Lamb, P.A.

Filed Under: Unsafe Drugs Tagged With: black-box drug label warning, blood clots, Cardiovascular death, Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Xeljanz

Find What You Want Here

Get Free Case Evaluation

We encourage you to submit an online Case Evaluation Form form – it is confidential and there is no obligation.

Or call our toll-free number, 800-426-9535, to speak directly to attorney Tom Lamb about your possible case.

Either way, you will get Mr. Lamb’s impressions about your case — and not that of a junior lawyer, paralegal, or (worse yet) some case-intake person.

Feel Free To Contact Us

Quick Contact Form
 
Send an Email to Tom Lamb

(800) 426-9535

Main Navigation Menu

  • Drug Injury Cases
  • Asbestos-Mesothelioma Cases
  • Benzene Disease Claims
  • GenX Cancer Cases
  • Breast Implant Cases
  • Case Evaluation Menu
  • Quick Contact Form
  • About Our Firm
  • Frequently Asked Questions
  • Medical Records Charges
  • Collection of Articles
  • Sitemap

Attorney Tom Lamb

Mr. Lamb is recognized by other lawyers as practicing law at the highest level of professional experience in terms of legal ability and ethical standards — which is indicated by an AV® Preeminent™ 5.0 out of 5 rating (highest classification) rating from the Martindale-Hubbell® Lawyer Directory.

More importantly, he received the Martindale-Hubbell® Client Distinction Award, which recognizes excellence for:

Quality of Service
Overall Value
Responsiveness
Communication Ability

Read More About Tom Lamb

Our Other Websites

Drug Injury Law
Drug Injury Watch
Drug Safety Developments
Asbestos & Mesothelioma
Asbestos HUB

Contact Information

Law Offices of Thomas J. Lamb, P.A.
1908 Eastwood Road, Suite 225
Wilmington, North Carolina 28403
910-256-2971 | 800-426-9535
TJL@LambLawOffice.com

  • Home
  • Frequently Asked Questions
  • Disclaimer and Copyright Notices

Copyright © 2019 · Law Offices of Thomas J. Lamb, P.A.